Evidence map›Paper›PMID 40283950›Full record

ArticlePharmaceuticals (Basel, Switzerland)2025

Differences in

Almudena Gil-Rodriguez, Sheila Recarey-Rama, Ana Rodríguez-Viyuela, Raquel Cruz, Francisco Barros, Angel Carracedo, Olalla Maroñas

Abstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Almudena Gil-RodriguezPharmacogenomics and Drug Discovery (GenDeM) Group, Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain.ORCID 0000-0002-7637-6915
Sheila Recarey-RamaPharmacogenomics and Drug Discovery (GenDeM) Group, Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain.ORCID 0009-0003-1623-1110
Ana Rodríguez-ViyuelaPharmacogenomics and Drug Discovery (GenDeM) Group, Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain.
Raquel CruzGenomic Medicine Group, CIMUS, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain.ORCID 0000-0002-6964-8898
Francisco BarrosCentre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, 28029 Madrid, Spain.ORCID 0000-0001-6895-4140
Angel CarracedoGenomic Medicine Group, CIMUS, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain.ORCID 0000-0003-1085-8986
Olalla MaroñasPharmacogenomics and Drug Discovery (GenDeM) Group, Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain.

Funding

Instituto de Salud Carlos III (ISCIII) through the "BioFRAM" project co-funded with European Union funds (NextGen). PMP22/00056
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

5-fluorouracilallele frequencyDPYDgenetic variationpopulational databases

Identifiers

PMID40283950
PMCPMC12030674

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.